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INTRODUCTION
Inflammation is a host defense process that occurs at injured
sites and is strictly regulated. The coordination of pro-inflam-
matory and anti-inflammatory mediators is important in the
regulation of the inflammatory response.
Historically, PMNs have been perceived as terminally dif-
ferentiated leukocytes with limited ability to produce de novo
protein. During acute inflammation, the first line of cellular
response for host defense is the PMNs, for they accumulate
in injured tissue. In addition to the historic role of the PMNs
as a phagocyte, recent studies have identified this cell as an
important source of a number of cytokines like IL-8 and
TNF- (1-5). Not only does PMNs play an important role in
the early inflammation of phagocytosis by various protease and
reactive oxygen, but also these cells can by themselves enhance
PMNs recruitment through a local production of IL-8.
Formyl methionyl leucyl phenylalanine (fMLP) is a typi-
cal chemoattractant. fMLP as a synthetic chemoattractant is
a family of formylated peptides, which are bacterial products
formed and released at the site of infection. It induces inflam-
mation on the PMNs and produces several cytokines in com-
bination with the fMLP receptors on the PMNs surface (6).
IL-4 and IL-10 are the biologic anti-inflammatory media-
tors. They play biologic anti-inflammatory roles so that they
inhibit the production and release of pro-inflammatory medi-
ators, such as IL-8 and TNF- , from monocytes and macro-
phages (7-9). Recent studies report that IL-4 or IL-10 has an
inhibitory effect on human PMNs-derived IL-8 or TNF-
release after lipopolysaccharides (LPS) stimulation (10-13).
But there have been few attempts to modify the hyper-inflam-
matory reaction of PMNs with biologic anti-inflammatory
mediators (14, 15). To modify the complex web of causality in
hyper-inflammation with biologic anti-inflammatory medi-
ators, a study on the regulation of PMN activities is a neces-
sary prerequisite.
The aim of this study was to investigate anti-inflammat-
ory effects on human PMNs by biologic anti-inflammatory
mediators, IL-4 and IL-10. In this study, we directly com-
pared the anti-inflammatory effects of IL-4 with IL-10 on
fMLP-induced human PMNs-derived IL-8 and TNF- .
MATERIALS AND METHODS
Human PMNs were isolated from healthy volunteers’
peripheral blood by the modified Boyum’ s method (16, 17).
Isolated human PMNs were incubated at 37℃with or with-
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Anti-inflammatory effects of IL-4 and IL-10 on Human
Polymorphonuclear Leukocytes
Inflammatory responses are strictly regulated by coordination of pro-inflammat-
ory and anti-inflammatory mediators. Interleukin-4 (IL-4) and interleukin-10 (IL-
10) have typically the biologic anti-inflammatory effects on monocytes, but
uncertain effects on polymorphonuclear leukocytes (PMNs). The PMNs are the
first line of cellular response for host defense during acute inflammation. To
modify hyper-inflammatory reaction with biologic anti-inflammatory mediators,
we have determined the biologic anti-inflammatory activities of IL-4 and IL-10 on
human PMNs. Human PMNs were pretreated with IL-4 or IL-10 and then stimu-
lated with formyl methionyl leucyl phenylalanine (fMLP) for times indicated. The
level of H2O2, interleukin-8 (IL-8) and tumor necrosis factor- (TNF- ) were
determined in the each cell free supernatants. fMLP plays the role of a typical
pro-inflammatory agent and, at least in determined conditions, down-regulated
TNF release. IL-4 acts as an anti-inflammatory mediator but IL-10 did not show
its anti-inflammatory activities on fMLP-stimulated human PMNs. IL-4 and IL-10
have different anti-inflammatory mechanisms. Perhaps, IL-10 needs co-factors
to act as an anti-inflammatory mediator. 
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out 10 nM fMLP (final concentration). Then, to demonstrate
inflammatory reaction by PMNs, the production of H2O2
was assessed by a flow cytometer. IL-8 and TNF- were deter-
mined in the cell-free supernatants by enzyme-linked immu-
nosorbent assay (ELISA) method.
Isolated PMNs were pretreated with 10 ng/mL IL-4 for 1
hr and then stimulated with 10 nM fMLP (final concentra-
tion) for the times indicated (0, 30 min, 2 hr, 4 hr, 20 hr).
The amounts of IL-8 and TNF- were obtained by the ELISA
method at each time.
Isolated PMNs were pretreated with 100 U/mL IL-10 for
45 min and then stimulated with 10 nM fMLP (final con-
centration) for the times indicated. The amounts of IL-8 and
TNF- were obtained in a similar fashion.
Buffers and cell preparation
To determine H2O2 production, calcium-free Dulbecco’ s
phosphate buffered saline (PBS) was purchased from Gibco
(Grand Island, NY, U.S.A.), pH 7.4. It contained 1.0 g/L D-
glucose (PBSg), it was freshly prepared. For experiments
involving PMNs stimuli, the PBSg contained 0.1 g/L CaCl2
(PBSg++).
Human PMNs were isolated by a modification of the
method by Boyum (16) as previously described. Briefly,
venous blood was drawn by using the aseptic technique from
healthy volunteers into tubes containing ethylene diaminester-
acetic acid (EDTA) as an anticoagulant. Carefully, 5.0 mL of
anticoagulated whole blood was layered over 5.0 mL of Poly-
morphprepTM (Nycomed Pharma AS, Oslo, Norway) in a 12
mL centrifuge tube. Care was taken to avoid mixing the blood
with the separation fluid. The samples were centrifuged and
layered over PolymorphprepTM for 500×g for 35 min in a
swing-out rotor at room temperature. After centrifugation,
two leukocyte’ s bands were visible. The top band at the sam-
ple/medium interface consisted of mononuclear cells and
the lower band of PMNs. The erythrocytes were pelleted.
The cell bands were harvested using a Pasteur pipette. The
resulting pellet was treated for 30 sec with 0.2% saline in
order to hemolyse remaining erythrocytes, and the suspen-
sion was then made isotonic by adding 1.8% saline (1:1, vol/
vol). The cells were washed, suspended in PBSg++, and spun
down (at room temperature, 450×g, 10 min). They were
resuspended in PBSg++ for stimulation. The total cell yield
was determined by counting a portion of the final suspen-
sion in a hemocytometer. We adjusted the concentration of
cells at 4-5×106 cells/mL. The differential cell counts were
determined by staining cytospin preparations with Diff-Quik
(Baxter Scientific Products, McGraw Park, IL, U.S.A.) and
counting across the entire slide. The differential was consis-
tently >95% PMNs and 2% lymphocytes. Monocytes typi-
cally represented <1% of cells. Viability was >95% as deter-
mined by trypan blue dye exclusion.
To avoid cell clumping following stimulation, EDTA was
employed in the final suspensions for flow cytometric analy-
sis. Cell centrifugation and washing was limited only to the
period following termination of reaction in order to minimize
handling artifacts.
Preparation of soluble stimuli
Formyl methionyl leucyl phenylalanine (fMLP, Sigma, St
Louis, MO, U.S.A.) was solublized in dimethyl sulfoxide
(DMSO, Sigma) at a 43.75 mg per 10 mL solution and diluted
with a working buffer (PBSg++) to a stock concentration
of 10-7 M. The final concentration of DMSO exposed to cells
was 0.01% (vol/vol). Recombinant human IL-4 (rH IL-4,
Sigma) was reconstituted and diluted to a stock concentra-
tion of 100 ng/mL with the working buffer. Recombinant
human IL-10 (rH IL-10, Sigma) was diluted in the working
buffer to a stock concentration of 10 U/mL. All stimulants
diluted to their stock concentrations were aliquoted into 0.5
mL volumes and stored for future use at -20℃. In each case,
addition of stimulant to cell suspension produced a 1: 10
dilution of its final concentration.
Intracellular hydrogen peroxide production
Measurement of intracellular H2O2 production was per-
formed according to the method by Bass and Parce (18).
This assay relies upon the fact that the fluorochrome (2′ , 7′ -
dichlorofluorescein) is trapped within the cell and unable to
leak out. Total cell fluorescence indirectly reflect intracellu-
lar hydrogen peroxide production and was measured by flow
cytometry.
Cells isolated as described above were suspended (106PMN/
mL) in PBSg and preincubated with 5.0  m 2′ ,7′ -dichlo-
rofluorescin diacetate (DCHF-DA, Sigma) in a final volume
of 5.0 mL with horizontal agitation at 37℃ for 15 min. To
avoid cell clumping following stimulation, EDTA (5 mM
final concentration) was employed after 15 min of preincu-
bation. The fluorescence of the cells at this point was referred
to as zero time. Cells were then exposed to the buffer alone
(control) or to a soluble stimulant (final concentration) fMLP
(10 nM) and incubated at 37℃ with agitation for the indi-
cated time periods. Reactions were terminated by addition
of cold PBSg and storage at 0-4℃.
Flow cytometric analysis
To measure the intracellular H2O2 production, cells were
analyzed by quantitative flow cytometry using Becton-Dick-
inson (San Jose, Ca, U.S.A.) FACScanTM, equipped with an
argon laser emitting light at 488 nm. Forward angle light
scatter and right angle light side scatter measurements were
used to differentiate PMNs from debris, cellular clumps, ery-
throcyte, and other leukocytes. Electronic gates were esta-
bilishd to include >95% PMN. We collected logarithmicEffects of IL-4 and IL-10 on Human Polymorphonuclear Leukocytes 9
list mode data for each sample on 10,000 events within the
PMN gates. Single parameter histograms were analyzed using
LYSYS II version 1.0 program running on a Hewlett-Packard
series 9153 computer.
Determination of IL-8 and TNF- Concentration by
ELISA
The concentrations of IL-8 and TNF- in the cell-free super-
natants were determined by ELISA. To determine IL-8 release,
the QuantiGlo human IL-8 kit (R&D Systems, U.S.A.) em-
ployed the quantitative immunometric sandwich enzyme
immunoassay technique. A microtiter plate coated with
murine monoclonal antibody (mAb) specific for IL-8 was
provided in the kit. Samples containing standard amounts of
recombinant IL-8 as well as study samples were added to
individual wells where any IL-8 present would bind to the
immobilized antibody. After four washes to remove any
unbound proteins, a polyclonal antibody specific against IL-
8 conjugated to horseradish peroxidase was added to the
wells. After another four washes, a luminol/peroxide substrate
was added and the color developed represented the amount
of IL-8 present. The reaction was stopped by adding 2N
sulfuric acid. The degree of color generated was determined
by measuring the optical density in a Luminometer (DML
2000. Digene. U.S.A.).
To determine TNF- release, the QuantiKine HS human
TNF kit (R&D System) employed the quantitative immuno-
metric sandwich enzyme immunoassay technique. A micro-
titer plate coated with murine anti-TNF mAb was provided
in the kit. Samples containing standard amounts of rTNF
as well as study samples were added to individual wells at
2-8℃for 14-20 hr. After four washes to remove any unbound
proteins, an alkaline phosphatase-conjugated anti-TNF pAb
was added to the wells, which were incubated for 3 hr at room
temperature. After another four washes, a NADPH substrate
was added and an amplifier enzyme and buffer containing
INT violet were added. The reaction was stopped by adding
2 N sulfuric acid. The degree of color generated was deter-
mined by measuring the optical density at 490/650 nm in
an EIA reader (Bio-Tec microplate reader, Bio-Tec Instrument.
U.S.A.).
Data analysis and statistics
All data were expressed as mean±SD (standard deviation).
Differences between paired experimental groups were com-
pared by Student t tests and only difference with p value less
than 0.05 was accepted as significant.
RESULTS
Intracellular H2O2 production from fMLP-stimulated
human PMNs
Mean fluorescence of 2′ ,7′ -dichlorofluorescein was detect-
ed by flow cytometry. At 15 min and 120 min post-stimu-
lation, mean fluorescence was 27.8±8.16 and 213.1±35.18,
respectively. Mean fluorescence of fMLP-stimulated PMNs
significantly increased with time (Fig. 1). Net fluorescences,
comparing fMLP-stimulated PMNs with non- stimulated
(buffer only) control PMNs, also increased significantly with
time (Fig. 2).
Release of IL-8 and TNF- from fMLP-stimulated
human PMNs
Isolated PMNs (4-5×106 PMN/mL) were stimulated with
10 nM fMLP for the indicated times up to 20 hr. As shown
in Table 1, control (non-stimulated) PMNs generated 3.1
±1.42 pg/mL to 496.7±344.09 pg/mL of IL-8 at the
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Fig.1 A: Following pre-incubation with 2′ ,7′ -dichlorofluorescein diacetate, PMNs were exposed to fMLP for time indicated. Mean fluores-
cence was detected by flow cytometer. Electronic gates were established to include >95% PMNs. B: Fluorescence of PMNs increased
with time after stimulation of 10 nM fMLP.
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time course, whereas stimulation with fMLP resulted in a
significant increase of constitutive PMNs-derived IL-8 by
123.4 times (472.9±220.34 pg/mL), 95.6 times (2741.6
±941.16 pg/mL) at 30 min and 2 hr after stimulation,
respectively (Table 1). When PMNs were stimulated with
fMLP, substantial up-regulation of IL-8 production was
observed (Fig. 3).
The release of TNF- from PMNs was slight compared to
the IL-8 release. However, TNF- release from control (non-
stimulated) PMNs were on the increase with time. When
PMNs were stimulated with fMLP, substantial down-regu-
lation of TNF- production was observed, as fMLP signifi-
cantly suppressed PMNs-derived TNF- release by 54%
(0.32±0.160 pg/mL), by 68% (0.25±0.069), at 4 hr and
20 hr post-stimulation, respectively (Fig. 3).
Effect of IL-4 and IL-10 on human PMNs-derived IL-8
We postulated that IL-4 and IL-10 may have an inhibito-
ry effect on the production of PMNs-derived IL-8. To test
this hypothesis, PMNs were pretreated with 10 ng/mL of
IL-4 for 1 hr or 100 U/mL of IL-10 for 45 min, and then
stimulated with 10 nM fMLP for the indicated times.
PMNs pretreated with IL-4 resulted in a significant sup-
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Fig. 3. Time courses of IL-8 and TNF- release by human PMNs stimulated with 10 nM fMLP and by control (not stimulated with fMLP).
PMNs (4, 5×10
6/mL) were stimulated with 10 nM fMLP for the times indicated. And IL-8 and TNF- were determined in the cell-free
supernatants by ELISA. *: p<0.05.
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Fig. 2. Time course of the net effects of intracellular hydrogen
peroxide production by fMLP. *: p<0.05.
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0 hr 0.5 hr 2 hr 4 hr 20 hr
IL-8 (pg/mL) Control* 3.1±1.42 4.1±1.16 47.8±34.55 120.4±96.93 496.7±344.09
fMLP
� 472.9±220.34 2741.6±941.16 1798.9±1619.77 3334.8±1953.59
TNF- (pg/mL) Control 0.17±0.028 0.17±0.019 0.34±0.047 0.68±0.091 0.95±0.568
p=0.001
fMLP 0.19±0.055 0.33±0.131 0.32±0.160 0.25±0.069
p=0.209 p=0.871 p=0.097 p=0.0003
Table 1. IL-8 and TNF- release by human PMNs after fMLP stimulation 
*PMNs (4-5×10
6/mL) were cultured without stimulation. 
� PMNs (4-5×10
6/mL) were stimulated for the times indicated with 10 nM fMLP. IL-8: Inter-
leukin-8. TNF- : Tumor nectosis factor-alpha. fMLP: formyl methionyl leucyl phenylalanine.Effects of IL-4 and IL-10 on Human Polymorphonuclear Leukocytes 11
pression of fMLP-stimulated PMNs-derived IL-8 release by
64% at 30 min post-stimulation and by 61% at 2 hr (Fig. 4).
fMLP-stimulated PMNs-derived IL-8 release from PMNs
were not significantly suppressed by pretreatment with IL-
10 (Fig. 4).
Effect of IL-4 and IL-10 on human PMNs-derived TNF-
We next postulated that IL-4 and IL-10 may have an anti-
inflammatory effect by suppression of the release of PMNs-
derived TNF- . To test this hypothesis, PMNs were pretreated
with IL-4 or IL-10, and then stimulated with fMLP in the
same manner.
PMNs pretreated with IL-4 resulted in a significant sup-
pression of fMLP-stimulated PMNs-derived TNF- release
by 12.9%, 36.8%, 34.4%, and 28.1%, in the indicated times
(Fig. 5).
There were no differences in TNF- release between IL-
10-pretreated PMNs and only fMLP-stimulated PMNs
through the experiment.
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Fig. 4. Net effects of IL-4 and IL-10 on IL-8 release by human PMNs through the experiment. Amounts of IL-8 from IL-4- and IL-10- pre-
treated PMNs were divided by the amounts of IL-8 from PMNs without pretreatment. *PMNs (4-5×10
6/mL) were pretreated with 10
ng/mL IL-4 for 1 hr and then stimulated with 10 nM fMLP for the times indicated. 
� PMNs (4-5×10
6/mL) were pretreated with 100 U/mL IL-
10 for 45 min and then stimulated with 10 nM fMLP for the times indicated. IL-8 was then determined in the cell-free supernatants by
ELISA. *: p<0.05.
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Fig. 5. Net effects of IL-4 and IL-10 on TNF- release by human PMNs through the experiment. Amounts of TNF- from IL-4 and IL-10
pretreated PMNs were divided by the amounts of TNF- from PMNs without pretreatment. PMNs (4-5×10
6/mL) were pretreated with 10
ng/mL IL-4 for 1 hr and with 100 U/mL IL-10 for 45 min and then stimulated with 10 nM fMLP for the times indicated. TNF- was deter-
mined in the cell-free supernatants by ELISA. *: p<0.0512 S.W. Lee, Y.S. Hong, C.M. Chun, et al.
DISCUSSION
When the human body’ s defense mechanisms are over-
whelmed and can no longer control their own inflammatory
and immunosuppressive response, the conditions are called
systemic inflammatory response syndrome (SIRS), sepsis,
and septic shock. The current hypothesis of the pathogene-
sis of SIRS, sepsis, and septic shock is an excessive produc-
tion/release of inflammatory mediators by excessive activation
of inflammatory cells and a parallel induction of immuno-
suppressive mediators with a depression of cellular immunity
(19-21). The production of many pro-inflammatory media-
tors and nitric oxide increase vascular permeability and
decrease effective circulating volume, disturbing the micro-
circulation to body tissues. The main consequences of these
responses to many organs are the onset of shock and the
development of a multiple organ dysfunction syndrome
(MODS) accompanied by a high mortality rate. The produc-
tion of pro-inflammatory mediators from inflammatory cells
is inhibited by immunosuppressive mediators, such as IL-4,
IL-10, IL-13, and prostagrandin E2, all of which have anti-
inflammatory characteristics (22). Therefore, a coordination
of pro-inflammatory mediators and anti-inflammatory medi-
ators is essential to regulate and to recover from inflamma-
tion (20, 21).
This hypothesis has prompted the introduction of new
treatment modalities for inflammation, which include anti-
endotoxin strategies to neutralize one of the proposed major
causal factors, an anti-inflammatory approach to modulate
the excessive systemic inflammatory response, and immu-
noaugmentation concepts to increase the potency of host
defense system (23). Anti-inflammatory approaches include
transcriptional and post-translational control of mediator
synthesis, control of release from inflammatory cells, bind-
ing with neutralizing molecules in the circulation, and thus
blocking the interaction between mediators and cell-surface
receptors. These approaches appeared to be effective in in
vitro studies. In clinical studies, however, they were not shown
to be operative. And there has been little attempt to modify
hyper-inflammatory reaction of PMNs with biologic anti-
inflammatory mediators (24).
fMLP is a traditional chemoattractant. In our study, fMLP
activated PMNs by increasing intracellular H2O2 production
and by releasing IL-8 after stimulation. This inflammatory
reaction is mediated by fMLP receptors on the PMNs sur-
face. fMLP and fMLP-receptor complex induces oxygen-free
radical production and the expression of IL-8 mRNA and
the synthesis of IL-8 protein (6, 25). IL-8 is described as a
chemoattractant for neutrophils or neutrophil chemotactic
factor (26, 27). IL-8 enhances the emigration of neutrophils
from the vascular compartment to the site of tissue inflam-
mation and activates neutrophils; causes degranulation and
increases respiratory burst and lysosomal enzyme release (28).
In addition to the historic role of the neutrophil as a phago-
cyte, PMNs are important in augmenting inflammation by
production of IL-8. IL-8 release was increased with time.
Without stimulation with fMLP, only test tube adhesion
induced IL-8 and TNF- release from PMNs. When stimu-
lated with fMLP, IL-8 release was explosively increased at 30
min and 2 hr post-stimulation. These results are similar to the
report of Cassatella et al. (1). They reported that the release
of IL-8 in response to fMLP was acute and transient.
In our study, fMLP did not induce TNF- release from
human PMNs. On the contrary, fMLP down-regulated test-
tube adhesion-induced TNF- release. This result is differ-
ent from the previous reports that showed the capability of
PMNs to secret newly synthesized TNF (1, 13). Those re-
searchers used LPS as a stimulant. LPS is the major compo-
nent of the outer membrane of gram-negative bacteria. For-
mylated peptides are the bacterial products formed and
released at the site of infection, and coexist with LPS. There
is not enough evidence for the relationships between LPS
and formylated bacterial peptides in the triggering and reg-
ulating of the immune inflammatory response. fMLP is best
characterized as a member of the formylated peptides family.
Vulcano et al. reported that fMLP reduced the expression of
the membrane form of TNF- on the PMNs surface (29) and
fMLP, a typical pro-inflammatory agent, could play, at least
in the determined conditions, an anti-inflammatory role (30).
In our study, fMLP had two different properties. It up-regu-
lated H2O2 production and IL-8 release from human PMNs
but down-regulated TNF- release.
IL-4 is known to originate from T-cell and causes activa-
tion and proliferation of B-cell. It is also a growth factor for
T-cell and exerts other effects on granulocytes (28). Other
investigators have demonstrated an inhibitory effect of IL-4
on the generation of pro-inflammatory mediators and reac-
tive oxygen metabolites from monocytes (31). We demon-
strated in this study that IL-4 had a significant suppressive
effect on fMLP-induced PMNs-derived IL-8 and TNF-
release. In other investigations, IL-4 regulates monocyte-
derived IL-8 both by inhibiting gene expression and by accel-
erating mRNA degradation (31). These mechanisms may
be operative in IL-4 regulation of PMNs-derived IL-8 and
TNF- , because PMNs and monocytes share the same stem
cell and may have similar conserved regulatory elements. Not
only do these results support the notion that the PMNs are
an active and dynamic participant of an inflammatory/im-
mune response through the activation of oxygen-free radical,
along with the production of IL-8 and TNF- , but they also
support the notion that these cells are also susceptible to
regulation by biologic anti-inflammatory mediators that
influence the direction of inflammatory response.
IL-10, a cytokine known to suppress the immune response,
originates from human monocytes, macrophages, and T and
B lymphocytes (28). IL-10 has been implicated in the regu-
lation of the functions of lymphoid and myeloid cells because
of its ability to suppress the synthesis of pro-inflammatoryEffects of IL-4 and IL-10 on Human Polymorphonuclear Leukocytes 13
cytokines from T-cells and monocytes/macrophages (7, 32,
33). Cassatella et al. reported that IL-10 diminished the lev-
els of TNF- and IL-8 mRNAs long after the onset of stim-
ulation of PMNs with LPS, and concluded that IL-10 is a
potent inhibitor of pro-inflammatory cytokines released from
PMNs stimulated with LPS (10). However, our results dif-
fered from theirs. In our study, IL-10 had no significant sup-
pressive effects on IL-8 and TNF- release from fMLP-stim-
ulated PMN. Cassatella et al. used LPS as a chemoattractant
(10). Because the chemotactic effects of LPS are mediated
by co-factors, such as LPS binding protein (19), we specu-
late that the anti-inflammatory effects of IL-10 might have
been mediated by co-factors, such as serum factors. Further
studies are necessary to unveil the anti-inflammatory mech-
anism of IL-10.
In our study, IL-4 exhibited an anti-inflammatory effects
on fMLP-stimulated PMN by inhibition of IL-8 and TNF-
release, but IL-10 was not shown to have any biologic anti-
inflammatory effects on fMLP-stimulated PMNs. Other
investigations have demonstrated anti-inflammatory effects
of IL-4 and IL-10, which inhibited the expression of IL-8
and TNF- mRNA and hence the synthesis of IL-8 and
TNF- (33). In our study, however, IL-4 and IL-10 showed
different anti-inflammatory effects. These results suggest that
IL-4 and IL-10 act through different anti-inflammatory
pathways.
There are some limitations in our study. We obtained only
a part of pro-inflammatory mediators from PMNs. There-
fore, we could not completely understand the mechanism of
anti-inflammatory reaction. For example, we did not com-
pletely understand the relation between fMLP and IL-4 for
down regulation effects on TNF release. Further investiga-
tion is warranted to determine the anti-inflammatory mech-
anisms of biologic anti-inflammatory mediators. We could
not directly apply these results to clinical conditions. In clini-
cal conditions, outcomes of the patients in the hyper-inflam-
matory conditions are subjected to various factors. Further
studies on the biologic anti-inflammatory mediators in clin-
ical conditions, such as sepsis and SIRS, are needed for clini-
cal application. Another limitation is that our attempts to
regulate PMNs activities are considered premature and no
longer adequate. Inflammatory responses are not simple
sequential reactions but chaotic in nature. Inflammatory
cells and mediators may have multiple and different proper-
ties in certain conditions. Therefore, to understand the com-
plex web of causality in hyper-inflammation, computer imple-
mentations of causal probabilistic networks combining the
learning by experience are needed in future studies.
In conclusion, fMLP induced inflammation on normal
human PMNs in vitro. fMLP up-regulated intracellular
hydrogen production and IL-8 release from human PMNs.
In contrast, fMLP down-regulated TNF- release. This study
has demonstrated that the fMLP-induced PMNs-derived
IL-8 and TNF- can be effectively modulated by endogenous
mediators, such as IL-4. Interestingly, in contrast to mono-
cytes and LPS stimulated PMNs, fMLP-stimulated PMNs
failed to respond to the suppressive effects of IL-10. We sug-
gest that the anti-inflammatory effects of IL-10 may be medi-
ated by co-factors, such as serum factors. IL-4 and IL-10 have
shown different anti-inflammatory effects. One inhibits IL-
8 and TNF- release from fMLP-stimulated PMNs, where-
as the other does not. These results suggest that IL-4 and
IL-10 have different anti-inflammatory mechanisms.
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